CUE
What one share of Cue Biopharma holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics engineered to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases.
Cue Biopharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $8.31 |
|---|---|
| Profit | −$36.22 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$11.07 |
| Cash and investments | $3.33 |
| Book value | $0.44 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$64.94 | $2.88 | −$36.82 | — | $94.98 |
| 2018 | $1.70 | −$58.08 | $2.76 | −$42.12 | — | $49.24 |
| 2019 | $4.71 | −$49.95 | $0.06 | −$41.98 | — | $61.65 |
| 2020 | $3.30 | −$46.83 | $0.62 | −$34.60 | — | $78.00 |
| 2021 | $14.33 | −$42.35 | $0.88 | −$38.12 | — | $61.01 |
| 2022 | $1.05 | −$44.61 | $0.14 | −$35.33 | — | $41.73 |
| 2023 | $3.60 | −$33.26 | $0.00 | −$26.20 | — | $23.56 |
| 2024 | $4.95 | −$21.66 | $0.04 | −$19.38 | — | $8.49 |
| 2025 | $8.70 | −$8.42 | $0.06 | −$6.92 | — | $8.21 |